Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma

Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-...

Full description

Bibliographic Details
Main Authors: Baumgarten, P. (Author), Behmanesh, B. (Author), Bernstock, J.D (Author), Dosch, M. (Author), Dubinski, D. (Author), Freiman, T.M (Author), Gessler, F. (Author), Keil, F. (Author), Miesbach, W. (Author), Seifert, V. (Author), Voss, M. (Author), Won, S.-Y (Author)
Format: Article
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2022
Subjects:
anticoagulant agent
Anticoagulants
complication
Direct oral anticoagulation
glioblastoma
Glioblastoma
Glioblastoma survival
Heparin, Low-Molecular-Weight
human
Humans
low molecular weight heparin
Low-molecular-weight heparin
lung embolism
Prospective Studies
prospective study
Pulmonary embolism
Pulmonary Embolism
Retrospective Studies
retrospective study
Therapeutic anticoagulation
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items